About iSTAR Medical
iSTAR Medical has exclusive rights to the STAR® material from the University of Washington in Seattle (USA) for ophthalmic use. The porous material exhibits outstanding anti-fibrotic and anti-inflammatory properties providing the foundation for the development of MINIjectTM, designed to be a best-in-class micro-invasive glaucoma surgery (MIGS) device. MIGS is the most promising and fastest-growing therapeutic option for the treatment of glaucoma. According to Market Scope, the fast-growing MIGS market is expected to reach $1.1bn worldwide by 2023.
iSTAR Medical’s management team and board have a successful track record in end-to-end product development, with proven clinical, regulatory and market access capabilities. The company is backed by specialised institutional and private investors.
Caution: investigational device not available for use or sale in the United States.